{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.1","upperLimit":"60.3","value":"19.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. DOR assessments were based on blinded central imaging review with confirmation. The DOR per RECIST 1.1 for all participants who experienced a confirmed CR or PR was reported per protocol for the first course of treatment.","dispersionType":"Full Range","groups":[{"description":"Participants receive pembrolizumab 200 mg IV Q3W for up to 35 treatments (approximately 2 years).","id":"OG000","title":"Pembrolizumab 200 mg"}],"paramType":"MEDIAN","populationDescription":"All allocated participants who received at least 1 dose of study treatment and who experienced a confirmed CR or confirmed PR. One previously reported participant was excluded from the DOR analysis based on a BICR re-read of prior scans after the primary analysis database lock.","reportingStatus":"POSTED","timeFrame":"Up to approximately 67 months","title":"Duration of Response (DOR) According to RECIST 1.1 Assessed by BICR","type":"SECONDARY","unitOfMeasure":"Months"}